Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio)

N/A

Report date: 2023/01/07 18:45:01

Base Information

Drug NameAnti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio)
Drug Alias NameAutologous CAR-T19/CAR-T22 cell therapy (Shenzhen BinDeBio)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDehe Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Bindebio Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A